Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects-Reference-Cited by-同舟云学术

Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects

Published:2016-05 Issue:5 Volume:38 Page:1228-1236.e1
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Bruderer Shirin,Okubo Kaori,Mukai Hideya,Mant Tim,Dingemanse Jasper

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference28 articles.

1. Mechanisms of disease: pulmonary arterial hypertension;Schermuly;Nat Rev Cardiol,2011

2. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation;Moncada;Nature,1976

3. Differential effects of stable prostacyclin analogues on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery;Clapp;Am J Respir Cell Mol Biol,2002

4. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor;Merritt;Br J Pharmacol,1991

5. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes;Coleman;Pharmacol Rev,1994

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Doses Evaluated in Clinical Pharmacology Studies Investigating the Effect of Intrinsic and Extrinsic Factors on PK and Safety: Case Examples from Approved Drug Development Programs;The AAPS Journal;2024-06-17

2. A Colon‐Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects;Clinical Pharmacology in Drug Development;2021-01-12

3. Selexipag for the treatment of pulmonary arterial hypertension;Expert Review of Respiratory Medicine;2020-12-31

4. Clinical evaluation of drug–drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers;British Journal of Clinical Pharmacology;2020-11-16

5. Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects;British Journal of Clinical Pharmacology;2020-06-05